We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Bristol-Myers, Honda, Danaher, MetLife and V.F.
Read MoreHide Full Article
For Immediate Release
Chicago, IL – Feb 26, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers (BMY - Free Report) , Honda (HMC - Free Report) , Danaher (DHR - Free Report) , MetLife (MET - Free Report) and V.F. Corp. (VFC - Free Report) .
Top Analyst Reports for Bristol-Myers, Honda and Danaher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers, Honda and Danaher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bristol-Myers’ shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last six months, gaining +13.4% vs. +4.4%. Bristol-Myers reported strong results for the fourth quarter beating on both earnings and sales. Strong sales of Opdivo and Eliquis contributed to the top line in the quarter.
In addition, the guidance for 2018 was encouraging. The Zacks analyst likes Bristol-Myers’ efforts to develop its pipeline, especially Opdivo. Several label expansion applications for Opdivo are under review in the United States and Europe. Potential approval will boost the prospects of these drugs. The positive results from the Checkmate-227 study for first-line treatment of lung cancer has already boosted prospects of approval.
However, pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain an overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to the adoption of Opdivo in adjuvant melanoma.
Shares of Honda have outperformed the Zacks Domestic Automotive industry over the last six months, increasing +28.1% vs. +21.5%. In third quarter of fiscal 2018 (ended Dec 31, 2017), Honda reported better-than-expected earnings. Revenues also came in higher than expectation. Through the Vision 2030 strategy plan, the company is focusing on strategies to boost coordination between research and development as well as procurement and manufacturing of its products.
The company is undertaking frequent collaborations to expand its business. The company has been recalling vehicles frequently over the last few years. Moreover, it has been facing a rise in R&D expenses and unfavorable foreign currency translation issues.
Danaher’s shares have gained +3.6% over the past three months, outperforming the Zacks Diversified Operations industry, which has declined -2.1% over the same period. Danaher kept its impressive earnings beat streak alive as its fourth-quarter 2017 adjusted earnings beat expectations.
The Zacks analyst is optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues.
However, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.
This apart, the company remains highly vulnerable to adverse foreign currency translations, as a significant portion of its revenues is derived from regions outside the United States.
Other noteworthy reports we are featuring today include MetLife and V.F. Corp.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Bristol-Myers, Honda, Danaher, MetLife and V.F.
For Immediate Release
Chicago, IL – Feb 26, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers (BMY - Free Report) , Honda (HMC - Free Report) , Danaher (DHR - Free Report) , MetLife (MET - Free Report) and V.F. Corp. (VFC - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Bristol-Myers, Honda and Danaher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers, Honda and Danaher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Bristol-Myers’ shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last six months, gaining +13.4% vs. +4.4%. Bristol-Myers reported strong results for the fourth quarter beating on both earnings and sales. Strong sales of Opdivo and Eliquis contributed to the top line in the quarter.
In addition, the guidance for 2018 was encouraging. The Zacks analyst likes Bristol-Myers’ efforts to develop its pipeline, especially Opdivo. Several label expansion applications for Opdivo are under review in the United States and Europe. Potential approval will boost the prospects of these drugs. The positive results from the Checkmate-227 study for first-line treatment of lung cancer has already boosted prospects of approval.
However, pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain an overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to the adoption of Opdivo in adjuvant melanoma.
(You can read the full research report on Bristol-Myers here >>>).
Shares of Honda have outperformed the Zacks Domestic Automotive industry over the last six months, increasing +28.1% vs. +21.5%. In third quarter of fiscal 2018 (ended Dec 31, 2017), Honda reported better-than-expected earnings. Revenues also came in higher than expectation. Through the Vision 2030 strategy plan, the company is focusing on strategies to boost coordination between research and development as well as procurement and manufacturing of its products.
The company is undertaking frequent collaborations to expand its business. The company has been recalling vehicles frequently over the last few years. Moreover, it has been facing a rise in R&D expenses and unfavorable foreign currency translation issues.
(You can read the full research report on Honda here >>>).
Danaher’s shares have gained +3.6% over the past three months, outperforming the Zacks Diversified Operations industry, which has declined -2.1% over the same period. Danaher kept its impressive earnings beat streak alive as its fourth-quarter 2017 adjusted earnings beat expectations.
The Zacks analyst is optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues.
However, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.
This apart, the company remains highly vulnerable to adverse foreign currency translations, as a significant portion of its revenues is derived from regions outside the United States.
(You can read the full research report on Danaher here >>>).
Other noteworthy reports we are featuring today include MetLife and V.F. Corp.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.